Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints

Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Aclidinium bromide;   Drug: Other COPD medication Sponsors:   AstraZeneca;   RTI Health Solutions Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials